Cargando…

Expression of p53 as a biomarker in determining response to apatinib for advanced gastric cancer

BACKGROUND: Apatinib has shown outstanding value in the treatment of advanced gastric cancer (AGC). However, no biomarkers are available to select AGC patients who will benefit from apatinib. The aim of the present study was to investigate the association between p53 and Ki67 expression of and the o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Qiu, Zhiyuan, Qin, Rong, Zhang, Ziyi, Zhang, Ting, Zhang, Zhao, Qiao, Chunyue, Xi, Yan, Tian, Guangyu, Wang, Yan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10466417/ https://www.ncbi.nlm.nih.gov/pubmed/37655112 http://dx.doi.org/10.3389/fonc.2023.1203980

Ejemplares similares

Apatinib combined with S-1 as second-line therapy in advanced gastric cancer
por: Qiu, Zhi-Yuan, et al.
Publicado: (2021)

Roles of intercellular cell adhesion molecule-1 (ICAM-1) in colorectal cancer: expression, functions, prognosis, tumorigenesis, polymorphisms and therapeutic implications
por: Qiu, Zhiyuan, et al.
Publicado: (2022)

Apatinib combined with PD-1 antibody for third-line or later treatment of advanced gastric cancer
por: Cui, Qingli, et al.
Publicado: (2022)

Efficacy and Response Biomarkers of Apatinib in the Treatment of Malignancies in China: A Review
por: Tian, Zhichao, et al.
Publicado: (2021)

Multiple-dose up-titration study to evaluate the pharmacokinetics, safety and antitumor activity of apatinib in advanced gastric adenocarcinoma
por: Wang, Yonggang, et al.
Publicado: (2022)

Treatment Response, Survival Benefit and Safety Profile of PD-1 Inhibitor Plus Apatinib Versus Apatinib Monotherapy in Advanced Colorectal Cancer Patients
por: Pan, Dengdeng, et al.
Publicado: (2022)

Anti-Tumor Effect of Apatinib and Relevant Mechanisms in Liposarcoma
por: Cui, Lixuan, et al.
Publicado: (2021)

Apatinib Treatment in Metastatic Gastrointestinal Stromal Tumor
por: Cai, Zhaolun, et al.
Publicado: (2019)

Apatinib plus chemotherapy for non-metastatic osteosarcoma: a retrospective cohort study
por: Wang, Jiaqiang, et al.
Publicado: (2023)

Efficacy of apatinib 250 mg combined with chemotherapy in patients with pretreated advanced breast cancer in a real-world setting
por: Zhang, Ruyan, et al.
Publicado: (2023)

Apatinib for salvage treatment of advanced malignant pleural mesothelioma: A case report
por: Du, Zedong, et al.
Publicado: (2018)

Remarkable Response of Metastatic Gallbladder Carcinoma to Apatinib After Failed Multiline Chemotherapies: A Case Report and Literature Review
por: Zhang, Mengxi, et al.
Publicado: (2019)

Apatinib Plus Temozolomide: An Effective Salvage Treatment for Recurrent Glioblastoma
por: Ge, Jingjing, et al.
Publicado: (2021)

Apatinib enhances chemosensitivity of gastric cancer to paclitaxel and 5-fluorouracil
por: Xu, Zhiyuan, et al.
Publicado: (2019)

Toxic Epidermal Necrolysis-Like Reaction Following Combination Therapy With Camrelizumab and Apatinib for Advanced Gallbladder Carcinoma
por: Yang, Yonghao, et al.
Publicado: (2021)

Apatinib Mesylate Inhibits the Proliferation and Metastasis of Epithelioid Malignant Peritoneal Mesothelioma In Vitro and In Vivo
por: Yang, Zhi-Ran, et al.
Publicado: (2020)

Apatinib-Induced Hand–Foot Skin Reaction in Chinese Patients With Liver Cancer
por: Xia, Hui, et al.
Publicado: (2021)

Efficacy and Safety of SBRT Combined With Camrelizumab and Apatinib in HCC Patients With PVTT: Study Protocol of a Randomized Controlled Trial
por: Hu, Yue, et al.
Publicado: (2020)

Assessment of Efficiency and Safety of Apatinib in Advanced Bone and Soft Tissue Sarcomas: A Systematic Review and Meta-Analysis
por: Long, Zuoyao, et al.
Publicado: (2021)

Transcatheter arterial chemoembolization combined with apatinib and camrelizumab for unresectable advanced gastric or gastroesophageal junction cancer: a single-arm, single-center, retrospective study
por: Wu, Kunpeng, et al.
Publicado: (2023)

Activity and safety of apatinib monotherapy or apatinib combined with chemotherapy for patients with metastatic or unresectable osteosarcoma over the age of 40 years: A retrospective analysis
por: Gong, Taojun, et al.
Publicado: (2022)

A novel therapeutic strategy of combined camrelizumab and apatinib for the treatment of advanced hepatocellular carcinoma
por: Yang, Qing, et al.
Publicado: (2023)

Evaluation of second-line apatinib plus irinotecan as a treatment for advanced gastric adenocarcinoma or gastroesophageal conjunction adenocarcinoma: a prospective, multicenter phase II trial
por: Qu, Jinglei, et al.
Publicado: (2023)

Efficacy and Adverse Events of Apatinib Salvage Treatment for Refractory Diffuse Malignant Peritoneal Mesothelioma: A Pilot Study
por: Yang, Zhi-Ran, et al.
Publicado: (2022)

Transarterial Chemoembolization Combined With Apatinib for Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis
por: Kan, Xuefeng, et al.
Publicado: (2020)

Efficacy and Safety of Apatinib Treatment for Advanced Cholangiocarcinoma After Failed Gemcitabine-Based Chemotherapy: An Open-Label Phase II Prospective Study
por: Zhang, Ge, et al.
Publicado: (2021)

Apatinib as an alternative therapy for advanced hepatocellular carcinoma
por: Zhang, Xi-Hao, et al.
Publicado: (2020)

Management of Apatinib-Related Adverse Events in Patients With Advanced Osteosarcoma From Four Prospective Trials: Chinese Sarcoma Study Group Experience
por: Xie, Lu, et al.
Publicado: (2021)

Is Treatment-Emergent Toxicity a Biomarker of Efficacy of Apatinib in Gastric Cancer?
por: Lee, Hyo Jin, et al.
Publicado: (2016)

Efficacy and safety of apatinib monotherapy for patients with advanced breast cancer: a systematic review and meta-analysis
por: Huang, Xuchen, et al.
Publicado: (2022)

The efficacy and safety of Apatinib in the treatment of advanced non-small cell lung cancer: A retrospective trial
por: Wang, Jijin, et al.
Publicado: (2022)

Novel Nutrition-Based Nomograms to Assess the Outcomes of Lung Cancer Patients Treated With Anlotinib or Apatinib
por: Zheng, Hui, et al.
Publicado: (2021)

MRI Radiomics Signature as a Potential Biomarker for Predicting KRAS Status in Locally Advanced Rectal Cancer Patients
por: Zhang, ZhiYuan, et al.
Publicado: (2021)

The combination of apatinib and S-1 for the treatment of advanced gastric cancer in China: A meta-analysis of randomized controlled trials
por: Liu, Yan, et al.
Publicado: (2018)

What Is the Most Suitable Agent Combined With Apatinib for Transarterial Chemoembolization Treatment in Advanced Hepatocellular Carcinoma Patients? A Systematic Review and Network Meta-analysis
por: Hui, Fuhai, et al.
Publicado: (2022)

Comprehensive Analysis of IGFBPs as Biomarkers in Gastric Cancer
por: Liu, Qi, et al.
Publicado: (2021)

Preoperative Chemoradiotherapy Versus Postoperative Chemoradiotherapy for Patients With Locally Advanced Gastric Cancer: A Retrospective Study Based on Propensity Score Analyses
por: Yang, Wang, et al.
Publicado: (2020)

Efficacy and safety of apatinib for the treatment of AFP-producing gastric cancer
por: Li, Ningning, et al.
Publicado: (2020)

Efficacy of the low dose apatinib plus deep hyperthermia as third-line or later treatment in HER-2 negative advanced gastric cancer
por: Han, Guohu, et al.
Publicado: (2023)

OSgc: A Web Portal to Assess the Performance of Prognostic Biomarkers in Gastric Cancer
por: Xie, Longxiang, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_cskvdjt1tjr3blrmsdf1u6foiu